Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock Short Interest Report for October

Posted by Francis Steltz on Oct 31st, 2026

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 17,259 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 112,857 shares, the days-to-cover ratio is currently 0.2 days.

Insider Activity at Frazier Life Sciences Acquisition Corp. II

In related news, CEO Albert Cha purchased 300,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the chief executive officer owned 300,000 shares of the company’s stock, valued at $3,000,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a report on Saturday, October 24th.

Check Out Our Latest Stock Report on Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC traded down $0.04 during trading on Friday, reaching $10.17. 3,763 shares of the company’s stock were exchanged, compared to its average volume of 141,373. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.10 and a 1 year high of $10.63.

About Frazier Life Sciences Acquisition Corp. II

(Get Free Report)

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.